2024 Prediction from Greg Baker
Greg Baker is the CEO of AffirmedRx. He predicts that "transparent PBMs will gain traction" in 2024.
We asked our readers and some members of our editorial advisory board to make predictions for 2024. Here's what Greg Baker said:
“In 2024, Optum Rx will follow suit with their own group purchasing organization (GPO) spinoff so they can take advantage of acquisition price models like CVS’ Averon and Express Scripts’
ClearNetwork. Several media outlets have compared these programs to the Mark Cuban Cost Plus Drug Company, but unlike Cost Plus, which fully discloses what it pays for medications, none of these GPOs will take a similar stance on disclosure.
Transparent PBMs will continue to gain traction in the market as traditional PBMs continue to lead employers to higher-cost, opaque models. Employers are told each year that their drug discounts will get better and their rebates will improve and yet every year their overall costs continue to increase.
Plan sponsors pharmaceutical costs will increase in 2024 and profits associated with companies that own traditional PBMs will see profit increases across all of their affiliate organizations.”
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Medicaid Expansion Linked To Timelier Lung Cancer Surgery and Access to High-Volume Hospitals
April 17th 2025New research shows that Medicaid expansion was linked to a 2.1% increase in timely lung cancer surgeries and a 2.8% rise in procedures at high-volume hospitals, highlighting how policy changes can impact cancer care access.
Read More
